Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 30.18
CPIX's Cash to Debt is ranked higher than
58% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.45 vs. CPIX: 30.18 )
Ranked among companies with meaningful Cash to Debt only.
CPIX' s Cash to Debt Range Over the Past 10 Years
Min: 1.16  Med: 12.61 Max: No Debt
Current: 30.18
Equity to Asset 0.85
CPIX's Equity to Asset is ranked higher than
81% of the 707 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. CPIX: 0.85 )
Ranked among companies with meaningful Equity to Asset only.
CPIX' s Equity to Asset Range Over the Past 10 Years
Min: 0.42  Med: 0.85 Max: 0.91
Current: 0.85
0.42
0.91
Interest Coverage 7.78
CPIX's Interest Coverage is ranked lower than
69% of the 467 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.06 vs. CPIX: 7.78 )
Ranked among companies with meaningful Interest Coverage only.
CPIX' s Interest Coverage Range Over the Past 10 Years
Min: 3.08  Med: 15.03 Max: 122.47
Current: 7.78
3.08
122.47
F-Score: 5
Z-Score: 4.60
M-Score: -2.78
WACC vs ROIC
10.04%
1.12%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 1.86
CPIX's Operating margin (%) is ranked lower than
68% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.72 vs. CPIX: 1.86 )
Ranked among companies with meaningful Operating margin (%) only.
CPIX' s Operating margin (%) Range Over the Past 10 Years
Min: -11.87  Med: 13.72 Max: 23.96
Current: 1.86
-11.87
23.96
Net-margin (%) 1.32
CPIX's Net-margin (%) is ranked lower than
69% of the 716 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.15 vs. CPIX: 1.32 )
Ranked among companies with meaningful Net-margin (%) only.
CPIX' s Net-margin (%) Range Over the Past 10 Years
Min: -6.57  Med: 9.08 Max: 24.72
Current: 1.32
-6.57
24.72
ROE (%) 0.56
CPIX's ROE (%) is ranked lower than
69% of the 744 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.16 vs. CPIX: 0.56 )
Ranked among companies with meaningful ROE (%) only.
CPIX' s ROE (%) Range Over the Past 10 Years
Min: -2.55  Med: 6.91 Max: 50.74
Current: 0.56
-2.55
50.74
ROA (%) 0.47
CPIX's ROA (%) is ranked lower than
67% of the 769 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.76 vs. CPIX: 0.47 )
Ranked among companies with meaningful ROA (%) only.
CPIX' s ROA (%) Range Over the Past 10 Years
Min: -2.26  Med: 5.30 Max: 24.03
Current: 0.47
-2.26
24.03
ROC (Joel Greenblatt) (%) 25.08
CPIX's ROC (Joel Greenblatt) (%) is ranked higher than
67% of the 762 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.16 vs. CPIX: 25.08 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CPIX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -43.4  Med: 92.21 Max: 1721.07
Current: 25.08
-43.4
1721.07
Revenue Growth (3Y)(%) -7.40
CPIX's Revenue Growth (3Y)(%) is ranked lower than
80% of the 602 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. CPIX: -7.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CPIX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -7.4  Med: 3.25 Max: 47.3
Current: -7.4
-7.4
47.3
EBITDA Growth (3Y)(%) -25.60
CPIX's EBITDA Growth (3Y)(%) is ranked lower than
89% of the 549 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. CPIX: -25.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CPIX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -25.6  Med: 2.50 Max: 109
Current: -25.6
-25.6
109
EPS Growth (3Y)(%) -47.40
CPIX's EPS Growth (3Y)(%) is ranked lower than
94% of the 503 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.70 vs. CPIX: -47.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CPIX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -47.4  Med: -14.80 Max: 33.5
Current: -47.4
-47.4
33.5
» CPIX's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-04)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

CPIX Guru Trades in Q2 2015

Chuck Royce 14,600 sh (+24.79%)
Jim Simons 196,700 sh (+15.58%)
John Rogers 1,505,086 sh (-21.09%)
» More
Q3 2015

CPIX Guru Trades in Q3 2015

Jim Simons 198,580 sh (+0.96%)
Chuck Royce 14,600 sh (unchged)
John Rogers 1,484,096 sh (-1.39%)
» More
Q4 2015

CPIX Guru Trades in Q4 2015

Jim Simons 217,200 sh (+9.38%)
Chuck Royce Sold Out
John Rogers 1,416,660 sh (-4.54%)
» More
Q1 2016

CPIX Guru Trades in Q1 2016

John Rogers 1,976,671 sh (+39.53%)
Jim Simons 222,600 sh (+2.49%)
» More
» Details

Insider Trades

Latest Guru Trades with CPIX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:BOM:590006, HKSE:00574, XKRX:191420, ROCO:4168, AMEX:PVCT, XKLS:7213 » details
Traded in other countries:CBJ.Germany,
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company. It is engaged in the acquisition, development and commercialization of branded prescription products. Its target markets are hospital acute care and gastroenterology.

Cumberland Pharmaceuticals Inc., was incorporated in Tennessee on January 6, 1999. It is a specialty pharmaceutical company which is engaged in the acquisition, development and commercialization of branded prescription products. It operates in a single operating segment of specialty pharmaceuticals products. Its product portfolio includes Acetadote (acetylcysteine) Injection for the treatment of acetaminophen poisoning, Caldolor (ibuprofen) Injection, the first injectable treatment for pain and fever approved in the United States, Kristalose (lactulose) for Oral Solution, a prescription laxative, and Hepatoren (ifetroban) injection, a Phase II candidate for the treatment of critically ill hospitalized patients suffering from hepatorenal syndrome (HRS). The Company's target markets are hospital acute care and gastroenterology, which are characterized by concentrated physician bases that it believe can be penetrated effectively by relatively small, targeted sales forces. The Company markets and sells its products through its dedicated hospital and gastroenterology sales forces in the United States, which together comprised more than 65 sales representatives and managers as of March 1, 2013. Acetadote is an intravenous formulation of N-acetylcysteine, or NAC, indicated for the treatment of acetaminophen poisoning. Caldolor, its intravenous formulation of ibuprofen, was the first injectable product approved in the United States for the treatment of both pain and fever. Kristalose is a prescription laxative administered orally for the treatment of constipation. Hepatoren is in Phase II clinical development. Pharmaceutical companies are subject to extensive regulation by national, state, and local agencies in the U.S. and additional regulations in other countries in which they do business. It promotes Acetadote and Caldolor through its dedicated hospital sales team and currently utilize two distinct sales teams to address its primary target markets: a hospital sales force for the acute care market and a field sales force for the gastroenterology market. It competes with the product attributes such as efficacy, safety, ease-of-use and cost-effectiveness.

Ratios

vs
industry
vs
history
P/E(ttm) 227.00
CPIX's P/E(ttm) is ranked lower than
96% of the 558 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.44 vs. CPIX: 227.00 )
Ranked among companies with meaningful P/E(ttm) only.
CPIX' s P/E(ttm) Range Over the Past 10 Years
Min: 12.4  Med: 52.46 Max: 302.94
Current: 227
12.4
302.94
PE(NRI) 227.00
CPIX's PE(NRI) is ranked lower than
95% of the 549 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.81 vs. CPIX: 227.00 )
Ranked among companies with meaningful PE(NRI) only.
CPIX' s PE(NRI) Range Over the Past 10 Years
Min: 12.55  Med: 52.44 Max: 257.5
Current: 227
12.55
257.5
Price/Owner Earnings (ttm) 90.80
CPIX's Price/Owner Earnings (ttm) is ranked lower than
78% of the 265 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.19 vs. CPIX: 90.80 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
CPIX' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 7.39  Med: 18.19 Max: 417.65
Current: 90.8
7.39
417.65
P/B 1.00
CPIX's P/B is ranked higher than
86% of the 762 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.80 vs. CPIX: 1.00 )
Ranked among companies with meaningful P/B only.
CPIX' s P/B Range Over the Past 10 Years
Min: 0.9  Med: 1.34 Max: 4.83
Current: 1
0.9
4.83
P/S 2.32
CPIX's P/S is ranked higher than
56% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.76 vs. CPIX: 2.32 )
Ranked among companies with meaningful P/S only.
CPIX' s P/S Range Over the Past 10 Years
Min: 1.66  Med: 2.64 Max: 6.8
Current: 2.32
1.66
6.8
PFCF 24.17
CPIX's PFCF is ranked higher than
54% of the 199 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.71 vs. CPIX: 24.17 )
Ranked among companies with meaningful PFCF only.
CPIX' s PFCF Range Over the Past 10 Years
Min: 12.85  Med: 30.05 Max: 1903.33
Current: 24.17
12.85
1903.33
POCF 17.39
CPIX's POCF is ranked higher than
52% of the 265 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.71 vs. CPIX: 17.39 )
Ranked among companies with meaningful POCF only.
CPIX' s POCF Range Over the Past 10 Years
Min: 11.4  Med: 18.32 Max: 1583.33
Current: 17.39
11.4
1583.33
EV-to-EBIT 28.61
CPIX's EV-to-EBIT is ranked lower than
66% of the 537 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.64 vs. CPIX: 28.61 )
Ranked among companies with meaningful EV-to-EBIT only.
CPIX' s EV-to-EBIT Range Over the Past 10 Years
Min: -17.8  Med: 10.20 Max: 90.4
Current: 28.61
-17.8
90.4
EV-to-EBITDA 7.73
CPIX's EV-to-EBITDA is ranked higher than
86% of the 569 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.81 vs. CPIX: 7.73 )
Ranked among companies with meaningful EV-to-EBITDA only.
CPIX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -56.6  Med: 8.10 Max: 35.6
Current: 7.73
-56.6
35.6
Shiller P/E 23.63
CPIX's Shiller P/E is ranked higher than
77% of the 146 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 46.77 vs. CPIX: 23.63 )
Ranked among companies with meaningful Shiller P/E only.
CPIX' s Shiller P/E Range Over the Past 10 Years
Min: 22.83  Med: 25.72 Max: 31
Current: 23.63
22.83
31
Current Ratio 5.83
CPIX's Current Ratio is ranked higher than
82% of the 662 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. CPIX: 5.83 )
Ranked among companies with meaningful Current Ratio only.
CPIX' s Current Ratio Range Over the Past 10 Years
Min: 1.45  Med: 5.80 Max: 14.46
Current: 5.83
1.45
14.46
Quick Ratio 5.46
CPIX's Quick Ratio is ranked higher than
83% of the 662 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.87 vs. CPIX: 5.46 )
Ranked among companies with meaningful Quick Ratio only.
CPIX' s Quick Ratio Range Over the Past 10 Years
Min: 1.38  Med: 5.36 Max: 13.46
Current: 5.46
1.38
13.46
Days Inventory 318.99
CPIX's Days Inventory is ranked lower than
94% of the 668 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.30 vs. CPIX: 318.99 )
Ranked among companies with meaningful Days Inventory only.
CPIX' s Days Inventory Range Over the Past 10 Years
Min: 92.58  Med: 381.63 Max: 636.33
Current: 318.99
92.58
636.33
Days Sales Outstanding 54.05
CPIX's Days Sales Outstanding is ranked higher than
69% of the 620 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.15 vs. CPIX: 54.05 )
Ranked among companies with meaningful Days Sales Outstanding only.
CPIX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 30.88  Med: 51.09 Max: 104.9
Current: 54.05
30.88
104.9
Days Payable 295.12
CPIX's Days Payable is ranked higher than
95% of the 589 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 71.47 vs. CPIX: 295.12 )
Ranked among companies with meaningful Days Payable only.
CPIX' s Days Payable Range Over the Past 10 Years
Min: 103.04  Med: 225.25 Max: 513.19
Current: 295.12
103.04
513.19

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.97
CPIX's Price/Net Cash is ranked higher than
89% of the 231 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.26 vs. CPIX: 1.97 )
Ranked among companies with meaningful Price/Net Cash only.
CPIX' s Price/Net Cash Range Over the Past 10 Years
Min: 1.37  Med: 2.18 Max: 6.72
Current: 1.97
1.37
6.72
Price/Net Current Asset Value 1.45
CPIX's Price/Net Current Asset Value is ranked higher than
93% of the 452 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.92 vs. CPIX: 1.45 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CPIX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.07  Med: 1.66 Max: 5.38
Current: 1.45
1.07
5.38
Price/Tangible Book 1.36
CPIX's Price/Tangible Book is ranked higher than
81% of the 708 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. CPIX: 1.36 )
Ranked among companies with meaningful Price/Tangible Book only.
CPIX' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.04  Med: 1.59 Max: 5.21
Current: 1.36
1.04
5.21
Price/Projected FCF 0.94
CPIX's Price/Projected FCF is ranked higher than
86% of the 311 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.53 vs. CPIX: 0.94 )
Ranked among companies with meaningful Price/Projected FCF only.
CPIX' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.73  Med: 1.11 Max: 1.59
Current: 0.94
0.73
1.59
Price/Median PS Value 0.89
CPIX's Price/Median PS Value is ranked higher than
72% of the 680 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.09 vs. CPIX: 0.89 )
Ranked among companies with meaningful Price/Median PS Value only.
CPIX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.65  Med: 1.02 Max: 2.46
Current: 0.89
0.65
2.46
Price/Graham Number 3.72
CPIX's Price/Graham Number is ranked lower than
76% of the 432 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.10 vs. CPIX: 3.72 )
Ranked among companies with meaningful Price/Graham Number only.
CPIX' s Price/Graham Number Range Over the Past 10 Years
Min: 0.81  Med: 1.90 Max: 3.95
Current: 3.72
0.81
3.95
Earnings Yield (Greenblatt) (%) 3.51
CPIX's Earnings Yield (Greenblatt) (%) is ranked higher than
55% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. CPIX: 3.51 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CPIX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.1  Med: 8.10 Max: 79.2
Current: 3.51
1.1
79.2
Forward Rate of Return (Yacktman) (%) -0.16
CPIX's Forward Rate of Return (Yacktman) (%) is ranked lower than
65% of the 323 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.36 vs. CPIX: -0.16 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
CPIX' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -0.4  Med: 3.60 Max: 17.8
Current: -0.16
-0.4
17.8

More Statistics

Revenue (TTM) (Mil) $32.57
EPS (TTM) $ 0.02
Beta1.10
Short Percentage of Float0.60%
52-Week Range $4.20 - 7.78
Shares Outstanding (Mil)16.22
» More Articles for CPIX

Headlines

Articles On GuruFocus.com
Speculative Options Buys Apr 29 2011 
Cumberland Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 11 2011 
Cumberland Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 15 2010 
Cumberland Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 16 2010 
Cumberland Pharmaceuticals Inc. Reports Operating Results (10-Q) May 17 2010 

More From Other Websites
CUMBERLAND PHARMACEUTICALS INC Financials May 20 2016
Cumberland Pharmaceuticals, Inc. :CPIX-US: Earnings Analysis: Q1, 2016 By the Numbers May 17 2016
CUMBERLAND PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition May 13 2016
Edited Transcript of CPIX earnings conference call or presentation 10-May-16 8:30pm GMT May 10 2016
CUMBERLAND PHARMACEUTICALS INC Files SEC form 8-K, Other Events May 10 2016
Cumberland reports 1Q loss May 10 2016
Cumberland reports 1Q loss May 10 2016
Cumberland Pharmaceuticals Reports First Quarter 2016 Financial Results May 10 2016
Cumberland Pharmaceuticals Reports First Quarter 2016 Financial Results May 10 2016
Clinigen Group and Cumberland Pharmaceuticals enter into exclusive U.S. commercialisation agreement... May 10 2016
Cumberland Pharmaceuticals and Clinigen Group enter into exclusive U.S. commercialization agreement... May 10 2016
Q1 2016 Cumberland Pharmaceuticals Inc Earnings Release - After Market Close May 10 2016
Cumberland Pharmaceuticals and Clinigen Group enter into exclusive U.S. commercialization agreement... May 10 2016
Cumberland Pharmaceuticals To Announce First Quarter 2016 Financial Results May 03 2016
Cumberland Pharmaceuticals To Announce First Quarter 2016 Financial Results May 03 2016
CUMBERLAND PHARMACEUTICALS INC Files SEC form 8-K, Other Events Apr 29 2016
How this Nashville health care company stocked its pipeline with the help of big pharma Apr 29 2016
Cumberland Pharmaceuticals Announces New Program To Develop Vasculan™ For Systemic Sclerosis Apr 27 2016
Cumberland Pharmaceuticals Announces New Program To Develop Vasculan™ For Systemic Sclerosis Apr 27 2016
Cumberland Pharmaceuticals Inc (CPIX): Ariel Investments Snapping Up Shares Apr 08 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)